In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for the fourth quarter of 2008. Our data comes from FDC-Windhover's Strategic Transactions.
Amanda Micklus and Maureen Riordan
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
Highlights from the Q4 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was only one-fourth that of Q3 with 57 deals bringing in over $1.09 billion, with no IPOs or FOPOs, but early-stage VC rounds accounting for 41% of this total. M&A dollars also were down: $7.6 billion in Q4--versus the $25.2 billion of the previous quarter--and contributing just 15% to the category's 2008 annual total. Alliances saw the most activity, boasting ten deals with pre-commercialization values greater than $100 million. Five of those were over $275 million, including Bristol-Myers Squibb Inc.'s $850 million tie up with Exelixis Inc., not only the fourth quarter's highest, but the second-largest alliance of the year.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.